Is BKHA or CELZ more undervalued in 2026?

CirclFi compares Black Hawk Acquisition Corporat (BKHA) and Creative Medical Technology Hol (CELZ) using 13 institutional-grade valuation models. BKHA has a Quality of Company score of 4.1/10 while CELZ scores 5.1/10.

Which is a better buy — BKHA or CELZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BKHA and CELZ valuations compare?

BKHA at $11.73 and CELZ at $2.25 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BKHA vs CELZ Valuation Comparison 2026 — Intrinsic Value Analysis

BKHA

Biological Products, (No Diagnostic Substances)

Black Hawk Acquisition Corporat

Quality

4.1

out of 10

Value Trap

—

Price

$11.73

Last close

Models

12/13

Active

CELZ

Biological Products, (No Diagnostic Substances)

Creative Medical Technology Hol

Quality

5.1

out of 10

Value Trap

WARN

Price

$2.25

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	BKHA Fair Value	BKHA Upside	CELZ Fair Value	CELZ Upside
Bayesian DCF	Intrinsic	$1.67	-86.0%	$1.46	-34.9%
Earnings Power Value	Intrinsic	$2.18	-81.7%	$1.63	-27.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BKHA vs CELZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BKHA vs CELZ — Which Stock Is More Undervalued?

CELZ scores higher with a 5.1/10 quality rating vs BKHA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Black Hawk Acquisition Corporat (BKHA) and Creative Medical Technology Hol (CELZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BKHA currently trades at $11.73 with a QOC of 4.1/10, while CELZ trades at $2.25 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).